The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes : an expert panel consensus statement. / Butler, Daniel C.; Simpson, Eric; Guttman-Yassky, Emma; Eichenfield, Lawrence F.; Golant, Alexandra K.; Koo, John Y.M.; Armstrong, April W.; Alexis, Andrew F.; Lio, Peter A.; Marson, Justin W.; Lebwohl, Mark.In: Journal of Dermatological Treatment, 2021.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - The atopic dermatitis spectrum disorder. Recognizing the clinical heterogeneity in patients with atopic related skin conditions in order to improve therapeutic decision-making and outcomes
T2 - an expert panel consensus statement
AU - Butler, Daniel C.
AU - Simpson, Eric
AU - Guttman-Yassky, Emma
AU - Eichenfield, Lawrence F.
AU - Golant, Alexandra K.
AU - Koo, John Y.M.
AU - Armstrong, April W.
AU - Alexis, Andrew F.
AU - Lio, Peter A.
AU - Marson, Justin W.
AU - Lebwohl, Mark
N1 - Funding Information: Dr. Simpson reports grants from Eli Lilly, Incyte, Kyowa Hakko Kirin, Leo Pharmaceutical, Merck, Pfizer, and Regeneron, and personal fees from Abbvie, Dermira, Eli Lilly, Forte Bio Rx, Incyte, Leo, Pfizer, Regeneron and Sanofi-Genzyme. Dr. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from Abbvie, Almirall, Amgen, AnaptysBio, Asana Biosciences, Boerhinger-Ingelhiem, Celgene, Dermavant, DS Biopharma, Eli Lilly, Galderma, Ichnos Sciences, Innovaderm, Janssen, Kiniska, Kyowa Kirin, Leo Pharma, Novan, Pfizer, Ralexar, Regeneron Pharmaceuticals, Inc., Sienna Biopharma, UCB and Union Therapeutics; and is a consultant for Abbvie, Aditum Bio, Almirall, Amgen, Asana Biosciences, AstraZeneca, Boerhinger-Ingelhiem, Cara Therapeutics, Celgene, Concert, DBV, Dermira, DS Biopharma, Eli Lilly, EMD Serono, Escalier, Galderma, Ichnos Sciences, Incyte Kyowa Kirin, Leo Pharma, Mitsubishi Tanabe, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi, Sienna Biopharma, Target PharmaSolutions and Union Therapeutics. Dr. Eichenfield serves as a consultant/speaker or on the advisory board for Almirall, Dermavant, Dermira, DS Biopharma, Forte, Galderma, Incyte, LEO, Lilly, L’Oreal, Matrisys, Otsuka, Novartis, Ortho Dermatologics/Valeant, Pfizer/Anacor, Regeneron, Sanofi-Genzyme and as an investigator for Abvie, LEO, Regeneron, Sanofi-Genzyme. Dr. Golant is a speaker for Regeneron/Sanofi Genzyme, Ortho Dermatologics and is a consultant/advisory board for AbbVie, Eli Lilly, UCB, Novartis, Dermira, and Janssen. Dr. Koo has served as an advisor for AbbVie, Amgen, Celgene, Janssen, Eli-Lilly, Leo Pharma, EPI, Novartis, Pfizer, Sun Pharma, and Ortho Dermatologics, Regeneron/Sanofi, UCB. Dr. Armstrong is an investigator for Sanofi Genzyme, Bristol-Myers Squibb, Dermavant, Dermira, Eli Lily, Galderma, Janssen – Ortho, Inc., Kyowa Hakko Kirin, Abbvie, Janssen Pharmaceuticals, Inc., Leo Pharma, Modernizing Medicine, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc, Regeneron Pharmaceuticals, Sun Pharma, UCB Pharma, a speaker for Abbvie, Regeneron Pharmaceuticals, and Sanofi Genzyme, and on the data safety monitoring board for Boehringer Ingelheim/Parexel. Dr. Alexis receives Grants/Research support form Leo, Novartis, Almirall, Bristol-Myers-Squibb, Celgene, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis, is a consultant for Leo, Novartis, Menlo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Unilever, Beiersdorf, Valeant, L’Oreal, BMS, Menlo, Scientis, Bausch health, UCB, Foamix, Cassiopea, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, is a speaker for Astra Zeneca, and royalties from Springer, Wiley-Blackwell, Wolters Kluwer. Dr. Lio reports research grants/funding from AOBiome, Regeneron/Sanofi Genzyme, and AbbVie; is on the speaker's bureau for Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, Galderma, and L'Oreal; reports consulting/advisory boards for Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos (stock options), L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs (stock options), Galderma, Verrica, Arbonne, Amyris, and Bodewell. In addition, Dr. Lio has a patent pending for a Theraplex product with royalties paid. Dr. Marson has no relevant conflict of interests to disclose. Dr. Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc and is a consultant for Aditum Bio, AnaptysBio, Almirall, Arcutis, Aristea, Arrive technology, Avotres Therapeutics, BioMx, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr.Reddy, Evelo, Evommune, Facilitate International Dermatologic Education, Forte, Foundation for Research and Education in Dermatology, Helsinn, LEO Pharma, Meiji, Mindera, Pfizer, and Verrica.
PY - 2021
Y1 - 2021
UR - http://www.scopus.com/inward/record.url?scp=85112524808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112524808&partnerID=8YFLogxK
U2 - 10.1080/09546634.2021.1966356
DO - 10.1080/09546634.2021.1966356
M3 - Letter
AN - SCOPUS:85112524808
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
SN - 0954-6634